Literature DB >> 27735037

Diagnostic and prognostic significance of E-cadherin and Ki-67 expression in non-small cell lung cancer patients.

L-Y He1, H Zhang, Z K Wang, H-Z Zhang.   

Abstract

OBJECTIVE: To elucidate the relationship between E-cadherin (E-cad) and Ki-67, and to determine their clinical significance in non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: A total of 68 NSCLC paraffin embedded tissue specimens and tumor-adjacent normal tissue specimens were collected. The expression of E-cad and Ki-67 was examined by immunohistochemistry and the relationships between the expression of these two markers were evaluated. The clinicopathological features were correlated with the expression of E-cad and Ki-67 to check whether these proteins have any association and if exist an association whether E-cad and Ki-67 can be used in diagnosis and prognosis of NSCLSC.
RESULTS: E-cad was expressed in all the normal tissues but Ki-67 expressed in only 5.8% of normal tissues. Ki-67 and E-cad expression were observed in 61.8% and 25% of NSCLC tissues respectively. Correlation analysis revealed an inverse association between the expression of E-cad and Ki-67 (r = 0.524, p = 0.000). The clinicopathological features such as tumor differentiation, TNM stage, lymph node metastasis and pleural invasion were all significantly associated with E-cad and Ki-67 expression (p < 0.05).
CONCLUSIONS: E-cad and Ki-67 together play a key role in the development, invasion and metastasis of NSCLC and combined detection of them serve as a potential marker for clinical diagnosis in addition to exploiting them as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27735037

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

1.  DWI and IVIM are predictors of Ki67 proliferation index: direct comparison of MRI images and pathological slices in a murine model of rhabdomyosarcoma.

Authors:  Yuan Yuan; Dewei Zeng; Yajie Liu; Juan Tao; Yu Zhang; Jie Yang; Tsendjav Lkhagvadorj; Zhenzhen Yin; Shaowu Wang
Journal:  Eur Radiol       Date:  2019-11-08       Impact factor: 5.315

2.  Predicting the Ki-67 proliferation index in pulmonary adenocarcinoma patients presenting with subsolid nodules: construction of a nomogram based on CT images.

Authors:  Jing Yan; Xing Xue; Chen Gao; Yifan Guo; Linyu Wu; Changyu Zhou; Feng Chen; Maosheng Xu
Journal:  Quant Imaging Med Surg       Date:  2022-01

Review 3.  Correlation between the Expression of VEGF and Ki67 and Lymph Node Metastasis in Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Dong Wei; Yunchao Xin; Yu Rong; Yanbing Hao
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-28       Impact factor: 2.650

4.  E-Cadherin and Syndecan-1 Expression in Patients With Advanced Non-small Cell Lung Cancer Treated With Chemoradiotherapy.

Authors:  Pinelopi Gkogkou; Evangelia Peponi; Dimitrios Ntaskagiannis; Samuel Murray; Asimo Demou; Ioannis Sainis; Elli Ioakeim; Evangelos Briasoulis; Pericles Tsekeris
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

5.  Elevated expression of mcl-1 inhibits apoptosis and predicts poor prognosis in patients with surgically resected non-small cell lung cancer.

Authors:  Qiuyuan Wen; Yuting Zhan; Hongmei Zheng; Hongjing Zang; Jiadi Luo; Yuting Zhang; Weiyuan Wang; Juan Feng; Junmi Lu; Lingjiao Chen; Songqing Fan
Journal:  Diagn Pathol       Date:  2019-10-10       Impact factor: 2.644

6.  Identification and validation of key genes with prognostic value in non-small-cell lung cancer via integrated bioinformatics analysis.

Authors:  Li Wang; Jialin Qu; Yu Liang; Deze Zhao; Faisal Ul Rehman; Kang Qin; Xiaochun Zhang
Journal:  Thorac Cancer       Date:  2020-02-14       Impact factor: 3.500

7.  CEA-Ki-67- Pathologic Subtype: An Adjunct Factor for Refining Prognosis in Stage I Pulmonary Adenocarcinoma.

Authors:  Dongzhi Yu; Yanbin Sun; Michael A McNutt; Shun Xu
Journal:  Front Surg       Date:  2022-04-25

8.  Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.

Authors:  Xiang Sun; Yang Xu; Yi Wang; Qian Chen; Liu Liu; Yangyi Bao
Journal:  Med Sci Monit       Date:  2018-05-15

9.  Clinicopathological characteristics of peripheral clinical stage IA lung adenocarcinoma with high Ki-67 expression.

Authors:  Zhan Liu; Hongxiang Feng; Shanwu Ma; Weipeng Shao; Jun Zhang; Zhaohua Zhang; Hongliang Sun; Xinlei Gu; Zhenrong Zhang; Deruo Liu
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.